Teva Beats Q4 Estimates with $4.71B Sales, Flagship Brands Hit $1B
Teva’s Q4 2025 revenue rose 11% year-over-year to $4.71 billion, topping the $4.37 billion consensus. Its key brands Austedo, Ajovy and Uzedy jointly hit $1 billion in quarterly sales, and management issued 2026 guidance of $16.4-$16.8 billion in revenue with adjusted EPS of $2.57-$2.77.
Related News
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
BBVA
BBVA Joins 25 Banks in 37-Member Qivalis Euro Stablecoin Consortium
BBVA•
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
HOOD
Robinhood Secures $3B Wells Fargo TradePMR Team, CFO to Present May 27
HOOD•
TSLA
Tesla Earns $890 Million From SpaceX and xAI With $131M Cybertruck Deal
TSLA•
Sources
RSBZG
+1 more